FIELD: medicine.
SUBSTANCE: invention relates to an antitumor agent comprising a 3,5-disubstituted benzene alkinyl compound or a salt thereof, which is administered in a mode of administration at least twice a week and a dosing interval of at least one day represented by the formula (I): 
, where R1 is the same or different and each represents C1-C6alkyl; X1 and X2 are independently N or CH; Y is a group represented by the formula: 
, where the bivalent fragment represented by 
, is C3-C10 a divalent heterocycloalkylene group containing at least one nitrogen atom in the ring and further containing in the ring from 0 to 2 identical or different heteroatoms selected from oxygen and sulfur (the remaining values are given in the formula); R2 is hydrogen, C2-C6alkynyl, -C(=O)ORx, -C(=O)N(Rx)(Ry), hydroxy-C1-C6alkyl, di(C1-C6alkyl)amino-C1-C6alkyl or a monocyclic or bicyclic C2-C9heteroaryl group containing from 1 to 3 identical or different heteroatoms selected from nitrogen, oxygen and sulfur, optionally containing R3; and R3 is C1-C6alkyl or di(C1-C6alkyl)amino-C1-C6alkyl; Z is -C(R4)=C(R5)(R6) or -C≡C-R7; R4, R5 and R6 are the same or different and each represents hydrogen, halogen, C1-C6alkyl optionally having R8, or R7 is hydrogen, C1-C6alkyl or hydroxy-C1-C6alkyl; R8 represents -ORx or -N(Rx)(Ry); R9 is C1-C6alkyl, halogen or -ORx; Rx and Ry are the same or different and each is hydrogen, C1-C6alkyl, C3-C10cycloalkyl, di(C1-C6alkyl)amino-C1-C6alkyl or C1-C6alkoxy-C1-C6alkyl; l is an integer of 0–3; m is an integer of 1–3; and n is an integer of 0–2 that provides a potent and highly selective novel FGFR inhibitor and an antitumor agent that has a reduction in side effects such as an increase in blood phosphorus levels while maintaining the antitumor effect of the FGFR inhibitor.
EFFECT: antitumor drug has been proposed for intermittent administration of an FGFR inhibitor.
24 cl, 6 dwg, 25 tbl, 73 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | 2013 |
|
RU2576384C1 |
| FGFR AND ITS MUTATION INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2021 |
|
RU2811207C1 |
| ANTITUMOUR EFFECT ENHANCER CONTAINING PYRROLOPYRIMIDINE COMPOUND | 2016 |
|
RU2710380C1 |
| NEW PYRROLOPYRIMIDINE COMPOUND OR ITS SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT, IN PARTICULAR, AGENT FOR PREVENTION AND / OR TREATMENT OF TUMORS AND SO ON, BASED ON INHIBITING INFLUENCE ON NAE | 2015 |
|
RU2658008C2 |
| NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | 2014 |
|
RU2666349C2 |
| QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | 2015 |
|
RU2721723C2 |
| PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| AGENT FOR PREVENTING AND/OR TREATING IMMUNE DISEASE | 2016 |
|
RU2705154C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
